ABOUT 1st_EBOIF
> AGENDA​
> REGISTRATION​
> ATTENDEES​
> INVESTORS​
> PRESENTERS
> EXHIBITORS​
> SPONSORS​
> SUPPORTERS​
> NETWORKING​
> VENUE​
> ACCOMMODATION

20-minute presenters

Aphaia Pharma AG

Aphaia Pharma is a clinical-stage biopharma company harnessing precision-targeted drug formulations to restore endogenous endocrine and neuroendocrine balance for the treatment of obesity and associated metabolic diseases.​

www.aphaiapharma.com

Rejuvenate Biomed NV

Rejuvenate Biomed is a clinical-stage company dedicated to the discovery and development of therapeutics to prevent or delay the onset of multiple age-related diseases.

Founded in 2017, Rejuvenate Biomed is a privately-held platform and pipeline company developing safe and proprietary combination drugs that help people healthy for life. By using platform technologies, Rejuvenate Biomed identifies safe compounds that influence the aging process. Novel combination drugs are discovered that have the potential to prevent or delay the onset of multiple age-related diseases. Rejuvenate Biomed confirms prediction data in preclinical models and in clinical studies.

Rejuvenate Biomed’s lead drug candidate RJx-01 is currently in Phase 1b for the treatment of sarcopenia, the progressive age-associated loss of muscle function and mass.

www.rejuvenatebiomed.com

Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory and Metabolic Care

Sen-Jam Pharmaceutical is pioneering a revolutionary approach to inflammatory and metabolic disorders with our proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) technology. By working with the body’s innate wisdom, our precision anti-inflammatories modulate inflammation at its source, addressing systemic risks linked to chronic conditions like obesity, metabolic dysfunction, and autoimmune diseases—all without suppressing the immune system. We are leading the next evolution in healthcare, delivering innovative treatments that enhance vitality, extend health spans, and redefine how the world heals.

What Problem Are We Solving?
Chronic inflammation is a silent driver of countless diseases, from metabolic disorders like obesity and MASLD to autoimmune and everyday health challenges. Yet, current treatments often suppress the immune system, creating new risks. The world needs a smarter, safer way to address inflammation and metabolic dysfunction at their core without compromising overall health. Sen-Jam Pharmaceutical’s breakthrough PAIR technology is designed to solve this urgent problem, offering precision anti-inflammatory and metabolic solutions that preserve vitality, support weight management, enhance productivity, and improve lives.

What’s Our Unfair Advantage?
Sen-Jam Pharmaceutical’s “unfair advantage” lies in the exceptional caliber of our team and the groundbreaking potential of our proprietary PAIR technology. Our scientific advisors, with decades of experience at world-renowned institutions like the Mayo Clinic, Boston Medical Center, Harvard School of Public Health are Ivy League-published experts solving the world’s toughest health challenges. This unparalleled expertise, combined with our precision-driven approach to inflammatory and metabolic care, positions Sen-Jam to disrupt the market and emerge as a transformative unicorn in healthcare.

www.sen-jam.com

Skye Bioscience, Inc.
[NASDAQ:SKYE]

Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

www.skyebioscience.com

VIVUS

We are a global pharmaceutical and biotechnology company.  We have three commercial products in weight loss, pancreatic enzyme replacement therapy and ED.  We have development products in endocrinology, pulmonary arterial hypertension and oncology.​

www.vivus.com

10-minute presenters

Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with eCOA, eDC, Digital Biomarkers and patient engagement tools (telehealth, eConsent, eRetention), drive the industry standard for precision data and usher in a new generation of clinical trials.​

www.clinicalink.com/

Rising Stars Session

Amaro Therapeutics, Inc.

Amaro Therapeutics is a preclinical platform company harnessing the extra‐oral bitter taste receptor (TAS2R) system—with an emphasis on human bitter taste receptor 1 (TAS2R1)—to develop novel small‐molecule therapeutics for metabolic diseases and diseases of aging. Although bitter taste receptors have been historically viewed as mediators of oral aversion, our thinking and emerging data suggest their primary function is nutrient‐sensing and further, the TAS2Rs system may be an endogenous system of deleterious cell clearance (i.e., cancer cells, senescent cells).  Ubiquitously expressed, TAS2R have demonstrated a clear immune-metabolic role in preclinical and clinical studies.  By targeting TAS2R1 agonism, Amaro hopes to restore healthy homeostasis by modulating metabolic pathways while simultaneously attenuating cellular senescence — all within a single therapeutic paradigm.​

www.amarotx.com

Lipotype GmbH

Lipotype is the leading lipidomics provider for all scientists. Our mass spectrometry-based platform can be applied to all biological samples, and is completed with data visualization and statistical analyses. Order your lipidomics, send in your samples, and get your data in as little as two weeks.​

www.lipotype.com

Primogene GmbH

We develop functional molecules for industries like pharma, early life and elderly nutrition, personal care, and cosmetics. We also offer chemicals for the R&D market, supporting innovation in these sectors. Using advanced biocatalysis methods and fermentation, we develop high-quality, sustainable molecules that help companies create better products for every stage of life.

If you are looking for a functional molecule, we offer an end-to-end solution—from R&D to full-scale production—ensuring the highest standards in quality and innovation for your product development.

www.primogene.bio

virtual showcases

MetaVia Inc.
[​Nasdaq: MTVA]

MetaVia Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases.

ir.metaviatx.com